2010
DOI: 10.2217/nnm.10.83
|View full text |Cite
|
Sign up to set email alerts
|

Immunoliposomal Systems Targeting Primary Effusion Lymphoma: In Vitro Study

Abstract: ILp could be proposed as effective carriers for oligonucleotide transfer in BCBL-1 cells. In vitro experimental results encourage us to further test the in vivo therapeutic potential of ILp for specific delivery of antitumoral agents.

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1

Citation Types

1
9
0

Year Published

2011
2011
2016
2016

Publication Types

Select...
6

Relationship

2
4

Authors

Journals

citations
Cited by 8 publications
(10 citation statements)
references
References 39 publications
1
9
0
Order By: Relevance
“…Liposomes (LPs) were prepared using cationic lipid DOTAP by thin layer evaporation method (TLE) followed by extrusion (Ruozi et al, 2010). Briefly, cationic lipid (5 mg) was dissolved in 2 ml of chloroform.…”
Section: Cationic Liposomesmentioning
confidence: 99%
“…Liposomes (LPs) were prepared using cationic lipid DOTAP by thin layer evaporation method (TLE) followed by extrusion (Ruozi et al, 2010). Briefly, cationic lipid (5 mg) was dissolved in 2 ml of chloroform.…”
Section: Cationic Liposomesmentioning
confidence: 99%
“…They have many advantages, including safety, stability, and lower immunogenicity 5, 6. Currently, the major types of non‐viral gene delivery vectors are cationic liposomes and cationic biomaterials 7, 8…”
Section: Introductionmentioning
confidence: 99%
“…5,6 Currently, the major types of non-viral gene delivery vectors are cationic liposomes and cationic biomaterials. 7,8 Biomaterials-based delivery platforms are gaining attention for their potential to control spatiotemporal distributions. Many efforts have been made to design new drug carrier systems that are able to improve the drug's solubility, stability, and target in vivo, while retaining its anticancer therapeutic efficacy.…”
Section: Introductionmentioning
confidence: 99%
“…9 Aiming to expand RNAi strategies for PEL treatment, we previously tested different lipid-based nanocarriers for their ability to target PEL cell lines efficiently. [10][11][12] In the present work, we investigated the in vitro and in vivo antineoplastic activity associated with liposomal siRNA-mediated knockdown of the BLIMP1/PRDM1 gene, which encodes Blimp-1, a transcription factor considered a crucial regulator of the transcriptional network in post-germinal center B-cell stages.…”
mentioning
confidence: 99%
“…[10][11][12] The same liposomes, either loaded with scrambled oligonucleotides (i.e. mock siRNA, commercially provided together with validated siRNA) or empty (vehicle), as well as free anti-BLIMP1 siRNA without a vehicle, were used as negative controls.…”
mentioning
confidence: 99%